← Back to Clinical Trials
Recruiting NCT07671846

NCT07671846 Patient Anxiety During Magnetic Resonance Imaging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07671846
Status Recruiting
Phase
Sponsor European Institute of Oncology
Condition Cancer
Study Type OBSERVATIONAL
Enrollment 175 participants
Start Date 2026-05-06
Primary Completion 2027-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 175 participants in total. It began in 2026-05-06 with a primary completion date of 2027-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is a cross-sectional validation project that aims to translate the MRI-Anxiety Questionnaire (MRI-AQ) into Italian and adapt it culturally for cancer patients undergoing whole-body MRI. The protocol will recruit 175 adult patients at the European Institute of Oncology, use a forward-backward translation process, and evaluate the Italian version with the MRI-AQ itself plus the MRI Fear Survey Schedule (MRI-FSS). The main statistical goal is to show that the Italian version is not inferior to the original in terms of internal consistency. The ultimate purpose is to provide a specific, validated tool for measuring MRI-related anxiety in Italian oncology patients.

Eligibility Criteria

Inclusion Criteria: * Cancer patients who will perform a WB-MRI in their clinical path * Age ≥ 18 years * Patients able to speak and read the local language(s) fluently. * Patients with no concomitant neurological or psychiatric disorders. * Acceptance and signature of informed consent Exclusion Criteria: * Absolute contraindication to WB-MRI * Previous cancer-related medical treatments or other treatments that could have altered patients' cognition

Contact & Investigator

Central Contact

Giuseppe Petralia, PhD

✉ giuseppe.petralia@ieo.it

📞 +39 0257489037

Frequently Asked Questions

Who can join the NCT07671846 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07671846 currently recruiting?

Yes, NCT07671846 is actively recruiting participants. Contact the research team at giuseppe.petralia@ieo.it for enrollment information.

Where is the NCT07671846 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT07671846 clinical trial?

NCT07671846 is sponsored by European Institute of Oncology. The trial plans to enroll 175 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology